Watson Pharmaceuticals (WPI -0.25%) sues the FDA for "improperly" denying the company's shared...
Watson Pharmaceuticals (WPI -0.25%) sues the FDA for "improperly" denying the company's shared exclusivity for a generic version of Type 2 diabetes drug Actos despite the firm following the agency's directions. As a result of the FDA's decision, Watson's abbreviated new drug application (ANDA) could be delayed for up to six months.
From other sites
Video at CNBC.com (Mon, 11:40AM)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 30, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs